Harbin Pharmaceutical Group announced that its subsidiary, Harbin Pharmaceutical Group Bioengineering, has received a Chemical API Marketing Authorization Approval Notice for potassium sulfate from the National Medical Products Administration. Potassium sulfate is one of the active pharmaceutical ingredients in the oral concentrated solution of magnesium sulfate, sodium sulfate, and potassium sulfate, acting as an osmotic laxative. Currently, there are 26 domestic companies with an A registration status for potassium sulfate API. The company has invested approximately 631,500 yuan in research and development.
Harbin Pharmaceutical Group Co LtdSubsidiary received marketing authorization approval for potassium sulfate API from NMPA.